Rare paediatric disease voucher programme makes long-awaited US return
After a lengthy period in regulatory limbo, the US Food and Drug Administration’s (FDA) rare paediatric disease priority review voucher …
Post
-
-
Eisai signs $388m deal for Japanese rights to Henlius’ anti-PD-1 mAb
Japanese pharmaceutical giant Eisai has forged an oncology licensing deal worth up to $388m with Shanghai Henlius Biotech. Through this deal, …
-
Everest Medicines and Micot partner on MT1013 commercialisation
Everest Medicines has signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific (excluding …
-
J.P. Morgan Healthcare Conference 2026 Report
The J. P. Morgan Healthcare Conference 2026 (JPM 2026) offers an early view of investor sentiment in the healthcare industry …
-
PrimeGen US and DT Cloud Star sign $1.5bn merger agreement
PrimeGen US and DT Cloud Star Acquisition have entered a definitive business combination agreement at an implied equity value of …
-
GSK’s oncology and HIV drugs drive 7% sales rise in 2025
GSK has posted positive sales results for fiscal year 2025 (FY2025) as the company’s new CEO, Luke Miels, takes the …
-
Eli Lilly soars past expectations to hit 45% sales growth in 2025
Booming sales for GLP-1RA drugs fuelled a 45% surge in Eli Lilly’s revenue for 2025, cementing the drugmaker’s dominant position …
-
Why pharma manufacturers are still investing in Europe
Undeterred by tariffs and global competition, pharma manufacturers are seeing an opportunity in Europe and continuing to invest accordingly. Europe’s share …
-
Novo Nordisk shares tumble 18% after 2026 sales dip warning
Shares in Novo Nordisk have plummeted after the drugmaker forecast a dip in sales and profit growth below analyst expectations …
-
Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer
Relay Therapeutics has received the US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for zovegalisib (RLY-2608), along with …
-
CEPI and Samsung Biologics partner to boost global vaccine preparedness
The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics have partnered in an outbreak-ready vaccine manufacturing partnership to enhance …
-
Pfizer sets sights on R&D strategy amid modest FY25 results
New York-based pharma giant Pfizer has met targets for its fiscal year 2025 (FY25) financials, which come as the company …
-
MSD’s 2026 sales forecast falls short amid patent losses despite strong Q4
Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more …
-
Podcast: driving linked data insights, the complexities, and experiences
This is the final episode in season one of Insights Uncovered: A Real-World Data Podcast Series from GlobalData, presented by …
-
SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal
SanegeneBio has entered a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its ribonucleic …
